1 / 24

WHO Collaborating Centre for Influenza - Australia

WHO Collaborating Centre for Influenza - Australia. SENTINEL PRACTICE REPORTS. 40. 1997. 1994. 1996. 1995. 30. 2000. 1993. 1998. 1992. 1999. 20. Rate/1000 consultations. 10. 0. Laboratory Diagnosed Influenza - Australia 1992-2000. 1000. TYPE A. 800. TYPE B. 600.

kamin
Télécharger la présentation

WHO Collaborating Centre for Influenza - Australia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHO Collaborating Centre for Influenza - Australia

  2. SENTINEL PRACTICE REPORTS 40 1997 1994 1996 1995 30 2000 1993 1998 1992 1999 20 Rate/1000 consultations 10 0 Laboratory Diagnosed Influenza - Australia 1992-2000 1000 TYPE A 800 TYPE B 600 Total laboratory diagnoses by month 400 200 0 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 1 4 7 10 92 93 94 95 96 97 98 99 00 Influenza in Australia 1992 - 2000

  3. 700 1996 600 1997 500 1998 1999 400 Rate per 100,000 2000 300 200 100 0 18 22 26 30 34 38 35 Flu A Flu B 30 25 20 Virus isolates 15 10 5 0 1 5 9 13 17 21 25 29 33 37 41 45 49 Week 2000 Influenza in New Zealand

  4. 50 45 B A(H3N2) 40 A(H1N1) 35 A(untyped) 30 25 20 15 10 5 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Monthly distribution of influenza isolates Thailand 2000

  5. Vietnam Taiwan Thailand South Africa Australia Singapore Philippines New Zealand New Caledonia Malaysia Source of Virus Isolates Analysed Jan 2000 - Jan 2001

  6. New Zealand Australia 13.8% 59.5% 41.1% A(H3N2) 36.8% 22.2% A(H1N1) 26.8% B Other Asia 53.1% 46.3% 12.2% 41.5% 20.7% 26.2% Distribution of Types/SubtypesJan 2000 - Jan 2001

  7. ANTISERUM A B C D E Sample Date Passage BAY/7 JOH/82 BEIJ/262 SING/9 NC/20 REF. Ag Human Sera Pool A A/BAYERN/7/95 1280 >2560 20 20 20 80 X,E5 B A/JOH’BURG/82/96 >2560 >2560 80 80 80 320 E4 C A/BEIJING/262/95 20 40 640 640 320 80 E5 D A/SINGAPORE/9/98 <20 <20 80 80 80 40 X,MD4 E A/NEW CALEDONIA/20/99 <20 <20 40 40 160 20 E5 TEST Ag A/JOH’BURG/31/2000 <20 <20 80 80 640 40 XE2 B/VICTORIA/526/2000 20 20 320 320 1280 80 MD2 15.09.00 A/C’CHURCH/95/2000 20 40 160 160 320 80 MD3 22.10.00 A/STH AUST/78/2000 20 80 320 320 640 80 MD2 16.09.00 A/WELLINGTON/8/2000 40 40 320 640 1280 160 MDX,MD1 A/AUCKLAND/100/2000 40 40 320 640 1280 160 MD3 29.08.00 A/STH AUST/157/2000 20 40 320 320 1280 80 MD2 23.10.00 A/PERTH/256/2000 20 20 160 320 640 80 MD2 21.09.00 A/PERTH/266/2000 20 20 320 320 640 80 MD2 25.09.00 Influenza A(H1) Analysis (1)

  8. Human ANTISERUM Sera Pool A B C D E F Passage Sample Date BAY/7 JOH/82 BEIJ/262 SING/9 NC/20 FUJ/156 REF. Ag A 1280 A/BAYERN/7/95 >2560 20 20 <20 <20 160 X,E5 B >2560 A/JOH’BURG/82/96 >2560 80 40 80 20 320 E5 C 1280 A/BEIJING/262/95 20 80 1280 640 320 80 E5 D 160 A/SINGAPORE/9/98 <20 <20 160 160 160 40 X,MD4 E 320 A/NEW CAL/20/99 <20 <20 80 640 640 20 E5 F 1280 A/FUJIAN/156/2000 <20 20 80 160 640 40 E2,E2,E1 TEST Ag A/PERTH/46/2000 80 80 640 1280 >2560 >2560 160 X,MD1 16.10.00 A/BANGKOK/335/2000 <20 <20 160 160 640 1280 80 E3,MD1 29.08.00 A/H.K./1841/2000 20 20 160 160 320 320 80 C2,C2,MD1 A/TEXAS/87/2000 <20 20 160 160 640 640 80 M1,C2,MD1 A/TEXAS/90/2000 640 >2560 20 20 20 20 160 M1,C2,MD1 A/WUHAN/292/2000 20 80 320 320 1280 >2560 160 E2,E2,E1 A/H.K./1924/2000 <20 <20 160 160 640 640 80 C2,C2,MD1 A/ENG/192/2000 80 320 80 40 160 40 160 C2,E1,E3 A/SING/37/2000 <20 20 160 160 640 1280 80 MD3 09.06.00 A/SING/44/2000 <20 <20 80 80 320 640 80 MD2 24.10.00 A/PERTH/16/2000 40 80 640 640 1280 >2560 160 X,MD1 04.09.00 A/PERTH/17/2000 40 40 320 640 >2560 >2560 80 X,MD1 07.09.00 Influenza A(H1) Analysis (2)

  9. Antigenic Analysis of A(H1N1) Isolates Jan - Aug 2000 Sept 2000 - Jan 2001

  10. Influenza A(H1N1) Isolates HA1 Sequence Analysis

  11. Influenza A(H1N1) Isolates NA Sequence Analysis

  12. Human Sera Pool Influenza A(H3) Analysis ANTISERUM Passage Sample Date A B C D E F REF. Ag SYD/5 MOS/10 PAN/2007 TEHRAN SYD/203 ULAN A 640 A/SYDNEY/5/97 640 640 640 1280 640 80 CEK2,E5 B >2560 A/MOSCOW/10/99 320 640 640 1280 1280 160 E7 C 640 A/PANAMA/2007/99 80 40 160 160 640 40 E7 D 1280 A/TEHRAN/14/99 160 640 640 1280 1280 80 X2,E3 E >2560 A/SYDNEY/203/2000 640 1280 640 640 1280 80 E4 F 1280 A/ULAN/UDE/01/2000 320 80 320 640 320 80 E6 TEST Ag A/VICTORIA/346/2000 320 1280 640 640 640 640 160 X,MD1 A/WELLINGTON/13/2000 80 320 320 320 320 320 40 MDX,MD1 A/WAIKATO/7/2000 640 1280 640 1280 1280 1280 80 MDX,MD1 A/WAIKATO/10/2000 320 1280 1280 1280 >2560 1280 160 MEKX,MD1 A/WAIKATO/14/2000 640 1280 1280 1280 >2560 >2560 320 MDX,MD1 A/WAIKATO/15/2000 320 640 640 640 640 640 80 MEKX,MD1 A/WAIKATO/17/2000 40 160 80 160 80 80 <20 MEKX,MD1 A/STH AUST/101/2000 40 160 160 160 160 160 20 MDX,MD1 28.09.00 A/STH AUST/136/2000 160 640 640 1280 1280 320 40 MDX,MD1 11.10.00 A/BRISBANE/71/2000 80 160 160 160 160 160 <20 MDX,MD1 20.09.00 A/BRISBANE/72/2000 80 640 640 640 1280 320 40 MDX,MD1 23.09.00 A/BRISBANE/75/2000 80 160 160 320 320 320 20 MDX,MD1 03.10.00

  13. A/Moscow 62.5% A/Moscow (low) 37.5% Antigenic Analysis of A(H3N2) Isolates Jan - Aug 2000 Sept 2000 - Jan 2001 A/Moscow (low) 14.0% A/Moscow 67.8% A/Sydney 5.9% A/Sydney (low) 12.3%

  14. Influenza A(H3N2) Isolates HA1 Sequence Analysis

  15. Influenza A(H3N2) Isolates NA Sequence Analysis

  16. ANTISERUM A B C D E F G BEIJ/184 YAM/166 SHEN/654 SICH/379 B/JOH/5 AUCK/1 JOH/45 PASSAGE SAMPLE DATE REF. Ag A 320 B/BEIJING/184/93 320 20 1280 320 320 640 E10 B 640 B/YAMANASH/166/98 320 40 >2560 640 640 640 E10 C 320 B/SHENZHEN/654/99 40 40 160 160 160 160 E8 D 640 B/SICHUAN/379/99 160 160 20 160 160 160 E11 E 320 B/JOHANNESBURG/5/99 160 160 20 1280 160 640 E5 F 320 B/AUCKLAND/1/2000 320 160 <20 320 160 320 CEK1E4 G 320 B/JOHANNESBURG/45/99 160 160 20 640 160 160 E8 TEST Ag B/VICTORIA/525/2000 160 40 160 320 320 160 320 MD2 13.09.00 B/CHRISTCHURCH/9/2000 80 20 160 320 160 160 160 MD3 30.08.00 B/CHRISTCHURCH/7/2000 160 40 160 640 640 320 640 MD2 16.08.00 B/VICTORIA/733/2000 160 20 160 160 320 160 160 MD2 22.08.00 B/VICTORIA/741/2000 80 40 160 320 320 160 320 MD2 05.09.00 B/VICTORIA/1/2000 160 40 160 640 640 640 640 MD1 B/SHANGHAI/72/99 160 160 20 640 320 160 320 E5 B/MEXICO/84/2000 160 80 40 640 320 160 320 E5 B/MADAGASCAR/50212/99 80 160 20 640 160 80 320 E6 Influenza B Analysis (1)

  17. Influenza B Analysis (2) ANTISERUM A B C D E PASSAGE SAMPLE DATE BEIJ/184 YAM/166 SICH/379 B/JOH/5 VIC/504 REF. Ag A 320 B/BEIJING/184/93 320 640 640 320 E10 B 320 B/YAMANASH/166/98 320 1280 320 160 E11 C 640 B/SICHUAN/379/99 160 160 320 320 E9 D 320 B/JOHANNESBURG/5/99 320 320 1280 320 E5 E 320 B/VICTORIA/504/2000 80 <20 160 160 CEK1E1 TEST Ag B/C’CHURCH/22/2000 160 40 640 320 640 MD3 02.10.00 B/VICTORIA/114/2000 160 80 640 320 640 MDX,MD1 26.09.00 B/VICTORIA/107/2000 160 20 320 160 320 MKX,MD1 16.08.00 B/WELLINGTON/21/2000 160 40 640 320 640 MD2 27.09.00 B/BRISBANE/30/2000 160 40 640 320 640 MDX,MD1 19.09.00 B/BRISBANE/38/2000 320 80 640 320 320 MDX,MD1 25.09.00 B/STH AUST/85/2000 80 <20 160 160 320 MDX,MD1 07.09.00 B/STH AUST/86/2000 80 20 320 160 320 MDX,MD1 07.09.00 B/VICTORIA/321/2000 80 <20 320 160 640 X,MD1 12.09.00

  18. Antigenic Analysis of Type B Isolates Jan - Aug 2000 Sept 2000 - Jan 2001 B/Beijing 60.3% B/Sichuan 2.9% B/Beijing 90.5% B/Shangdong 6.7% B/Sichuan 39.7%

  19. Brisbane/4/00 [8/00] Sth Australia/24/00 [7/00] Influenza B Isolates HA1 Sequence Analysis Victoria/541/00 [10/00] California/6/00cdc [11/00] Canada/16188/00cdc [11/00] LYS 58 PHE Washington/3/00cdc [12/00 ] ASN 126 ASP Victoria/520/00 [9/00] Victoria/529/00 [9/00] New York/2/00cdc [12/00] Sth Australia/47/00 [8/00] Hong Kong/548/00nimr [9/00] Sydney/217/00 [8/00] Hong Kong/564/00nimr [10/00] Johannesburg/5/99 Moscow/4/00nimr [4/00] Buenos Aries/R64/00nimr [6/00] ASN 196 ASP Hong Kong/533/00nimr [6/00] ASP 232 GLU Victoria/502/00 [7/00] Shizuoka/480/00niid Victoria/504/00 [8/00] Sichuan/379/99 Washington/2/00cdc [9/00] Sth Australia/5/99 Christchurch/5/00 [7/00] ILE 87 VAL Lisbon/3/00nimr [10/00] LYS 88 ARG Alaska/16/00cdc [11/00] Sendai/H518/00cdc Sydney/201/00 [7/00] Gaungdong/120/00cdc [3/00] Perth/2/00 [5/00] Victoria/527/00 [9/00] Brazil/975/00cdc Auckland/3/00 [6/00] ALA 28 VAL Perth/1/00 [2/00] ARG 69 SER Bangkok/29/00 [ 1/00] ALA 127 ILE Singapore/25/00 [8/00] LYS 149 ARG Osako/C-1/00 Victoria/503/00 [8/00] Argentina/113/00cdc [ 8/00] Yamanshi/166/98 Hong Kong/557/00cdc [10/00] Taiwan/2/00 [3/00] Shenzhen/654/99 Philippines/289/00 [5/00] Hong Kong/588/00cdc [10/00] Beijing/184/93 Harbin/7/94 Beijing/243/97 Shangdong/7/97 7.9 6 4 2 0

  20. Influenza B Isolates NA Sequence Analysis

  21. 400 New Cal/20/99 Auck/32/2000 300 Joh/82/96 Texas/87/2000 Wuhan/292/2000 200 100 0 USA GMT USA >40 Aust GMT Aust >40 Influenza Type A(H1N1) VaccineResponses - Older Adults 2000

  22. 160 140 Sydney/5/97 Panama/2007/99 120 Tehran/14/99 Sydney/203/2000 Ulan Ude/1/2000 100 VBrazil/991/2000 Fujian/40/2000 Hong Kong/1923/2000 80 Lyon/1242/2000 60 40 20 0 USA GMT USA >40 Aust GMT Aust >40 Influenza Type A(H3N2) VaccineResponses - Older Adults 2000

  23. 120 Yamanashi/166/98 Joh/5/99 100 Sichuan/379/99 Auckland/1/2000 80 Christchurch/2/2000 Zagreb/3578/99 60 Victoria/504/2000 Alaska/16/2000 40 Series 9 20 0 USA GMT USA >40 Aust GMT Aust >40 Influenza Type B VaccineResponses - Older Adults 2000

More Related